MedTrace Logo

A Study of ABT-072 in Healthy and Hepatitis C Virus Genotype 1-Infected Adults

NCT00752687 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2010-10-21

No results posted yet for this study

Summary

To evaluate the safety, tolerability and pharmacokinetics of ABT-072 in healthy volunteers and its anti-viral activity in HCV infected subjects.

Conditions

  • Hepatitis C

Interventions

DRUG

ABT-072

Capsule or powder drug substance from the capsule mixed in an alternative vehicle. For additional information refer to Arm Description.

DRUG

placebo

Capsule, or powder drug substance from the capsule mixed in an alternative vehicle. For additional information refer to Arm Description.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2009-05-31

Countries

  • United States

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00752687 on ClinicalTrials.gov